| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Meningococcal Infections | 16 | 2021 | 216 | 6.59 | Why? |
| Meningococcal Vaccines | 14 | 2021 | 225 | 5.12 | Why? |
| Pneumococcal Infections | 12 | 2021 | 562 | 4.92 | Why? |
| Streptococcus pneumoniae | 12 | 2021 | 827 | 3.32 | Why? |
| Pneumococcal Vaccines | 12 | 2019 | 571 | 3.17 | Why? |
| Neisseria meningitidis, Serogroup B | 9 | 2019 | 66 | 2.62 | Why? |
| Vaccines, Conjugate | 9 | 2019 | 328 | 2.56 | Why? |
| Neisseria meningitidis | 7 | 2021 | 229 | 2.54 | Why? |
| England | 38 | 2021 | 5116 | 2.24 | Why? |
| Serogroup | 11 | 2019 | 510 | 2.15 | Why? |
| Heptavalent Pneumococcal Conjugate Vaccine | 4 | 2019 | 64 | 1.79 | Why? |
| Meningitis, Meningococcal | 4 | 2019 | 114 | 1.19 | Why? |
| Schools | 8 | 2021 | 4187 | 1.11 | Why? |
| Wales | 11 | 2018 | 758 | 1.08 | Why? |
| Health Priorities | 2 | 2021 | 959 | 0.91 | Why? |
| Anemia, Sickle Cell | 2 | 2019 | 546 | 0.89 | Why? |
| Educational Personnel | 1 | 2021 | 76 | 0.88 | Why? |
| Immunization Programs | 10 | 2019 | 2006 | 0.84 | Why? |
| Haemophilus Infections | 2 | 2017 | 69 | 0.84 | Why? |
| Infant | 35 | 2021 | 30274 | 0.80 | Why? |
| Meningitis, Aseptic | 1 | 2019 | 22 | 0.80 | Why? |
| Vaccines, Combined | 1 | 2019 | 67 | 0.77 | Why? |
| Child, Preschool | 32 | 2021 | 36283 | 0.77 | Why? |
| Haemophilus influenzae type b | 1 | 2017 | 30 | 0.72 | Why? |
| Penicillin Resistance | 1 | 2017 | 15 | 0.71 | Why? |
| Stillbirth | 3 | 2021 | 544 | 0.69 | Why? |
| Antibodies, Bacterial | 2 | 2017 | 510 | 0.65 | Why? |
| Nursing Homes | 5 | 2021 | 4155 | 0.65 | Why? |
| Child | 39 | 2021 | 70012 | 0.64 | Why? |
| London | 10 | 2021 | 2166 | 0.63 | Why? |
| Diphtheria-Tetanus-acellular Pertussis Vaccines | 1 | 2017 | 91 | 0.63 | Why? |
| Complement System Proteins | 1 | 2019 | 380 | 0.59 | Why? |
| Infant, Newborn | 28 | 2021 | 23105 | 0.58 | Why? |
| Hepatitis A | 1 | 2017 | 140 | 0.58 | Why? |
| Immunologic Deficiency Syndromes | 1 | 2019 | 368 | 0.57 | Why? |
| Enterovirus B, Human | 1 | 2014 | 124 | 0.53 | Why? |
| Medical Staff | 1 | 2020 | 723 | 0.53 | Why? |
| Enterovirus Infections | 2 | 2018 | 404 | 0.52 | Why? |
| Infant, Newborn, Diseases | 2 | 2018 | 394 | 0.50 | Why? |
| Adolescent | 33 | 2021 | 86841 | 0.47 | Why? |
| Meningoencephalitis | 1 | 2014 | 208 | 0.46 | Why? |
| Seroepidemiologic Studies | 11 | 2021 | 10017 | 0.44 | Why? |
| Incidence | 19 | 2021 | 25622 | 0.44 | Why? |
| United Kingdom | 21 | 2021 | 18046 | 0.44 | Why? |
| Serotyping | 4 | 2019 | 154 | 0.44 | Why? |
| Opportunistic Infections | 1 | 2017 | 602 | 0.44 | Why? |
| Disease Transmission, Infectious | 5 | 2021 | 9044 | 0.44 | Why? |
| Mass Screening | 2 | 2021 | 8005 | 0.42 | Why? |
| Prenatal Care | 2 | 2020 | 1314 | 0.42 | Why? |
| Child Health | 1 | 2020 | 940 | 0.42 | Why? |
| Mass Vaccination | 1 | 2021 | 1101 | 0.41 | Why? |
| Students | 6 | 2021 | 5255 | 0.41 | Why? |
| Prospective Studies | 17 | 2021 | 43301 | 0.41 | Why? |
| Homes for the Aged | 1 | 2020 | 1071 | 0.41 | Why? |
| Streptococcus agalactiae | 3 | 2021 | 194 | 0.39 | Why? |
| Vaccination | 14 | 2021 | 19050 | 0.39 | Why? |
| Respiratory Tract Infections | 6 | 2021 | 6817 | 0.38 | Why? |
| Humans | 94 | 2021 | 930598 | 0.37 | Why? |
| Hepatitis B | 1 | 2017 | 888 | 0.37 | Why? |
| Population Surveillance | 6 | 2021 | 4967 | 0.36 | Why? |
| Candidemia | 1 | 2013 | 353 | 0.36 | Why? |
| Candida | 1 | 2013 | 425 | 0.36 | Why? |
| Public Health | 8 | 2021 | 16359 | 0.35 | Why? |
| Penicillins | 2 | 2019 | 132 | 0.33 | Why? |
| Meningitis, Bacterial | 2 | 2018 | 111 | 0.32 | Why? |
| Patient Acceptance of Health Care | 3 | 2020 | 5002 | 0.32 | Why? |
| Ireland | 4 | 2020 | 1456 | 0.31 | Why? |
| Immunization Schedule | 3 | 2019 | 1305 | 0.31 | Why? |
| Disease Outbreaks | 6 | 2021 | 27595 | 0.31 | Why? |
| Female | 54 | 2021 | 380317 | 0.31 | Why? |
| Time-to-Treatment | 2 | 2020 | 5883 | 0.30 | Why? |
| Fever | 5 | 2021 | 7795 | 0.30 | Why? |
| Rotavirus Vaccines | 2 | 2019 | 203 | 0.29 | Why? |
| Streptococcal Infections | 2 | 2018 | 255 | 0.29 | Why? |
| Male | 43 | 2021 | 367725 | 0.26 | Why? |
| Rotavirus Infections | 2 | 2019 | 355 | 0.26 | Why? |
| Risk Factors | 16 | 2021 | 71621 | 0.25 | Why? |
| Antibody Formation | 3 | 2021 | 4038 | 0.25 | Why? |
| Gastroenteritis | 2 | 2019 | 489 | 0.24 | Why? |
| Whole Genome Sequencing | 4 | 2021 | 3239 | 0.24 | Why? |
| Seroconversion | 3 | 2021 | 2515 | 0.24 | Why? |
| Pharynx | 2 | 2021 | 1544 | 0.23 | Why? |
| Neisseria meningitidis, Serogroup C | 2 | 2019 | 46 | 0.23 | Why? |
| Occupational Exposure | 1 | 2020 | 4742 | 0.22 | Why? |
| Cross Infection | 3 | 2020 | 8675 | 0.22 | Why? |
| Meningitis, Pneumococcal | 2 | 2018 | 35 | 0.22 | Why? |
| Emigration and Immigration | 1 | 2006 | 501 | 0.21 | Why? |
| Coinfection | 1 | 2021 | 6820 | 0.21 | Why? |
| Haemophilus influenzae | 2 | 2021 | 196 | 0.20 | Why? |
| Polysaccharides, Bacterial | 1 | 2019 | 59 | 0.19 | Why? |
| Antibodies, Monoclonal, Humanized | 2 | 2019 | 9335 | 0.19 | Why? |
| Streptococcal Vaccines | 1 | 2018 | 31 | 0.19 | Why? |
| Pregnancy | 12 | 2021 | 23879 | 0.19 | Why? |
| Infection Control | 4 | 2021 | 23131 | 0.19 | Why? |
| Cohort Studies | 8 | 2021 | 36005 | 0.18 | Why? |
| Antibodies, Viral | 9 | 2021 | 51949 | 0.18 | Why? |
| Young Adult | 16 | 2021 | 93724 | 0.18 | Why? |
| Neonatal Sepsis | 1 | 2018 | 69 | 0.17 | Why? |
| Haemophilus Vaccines | 1 | 2017 | 76 | 0.17 | Why? |
| Biostatistics | 1 | 2019 | 116 | 0.17 | Why? |
| Otitis Media | 1 | 2019 | 106 | 0.17 | Why? |
| Pregnancy Complications, Infectious | 5 | 2021 | 11559 | 0.17 | Why? |
| Antipyretics | 1 | 2017 | 107 | 0.17 | Why? |
| Bordetella pertussis | 1 | 2017 | 117 | 0.16 | Why? |
| Aged, 80 and over | 12 | 2021 | 88759 | 0.16 | Why? |
| Meningitis | 1 | 2018 | 163 | 0.16 | Why? |
| Age Factors | 5 | 2021 | 21039 | 0.16 | Why? |
| Pneumonia, Pneumococcal | 1 | 2019 | 251 | 0.16 | Why? |
| Antigenic Variation | 1 | 2017 | 249 | 0.16 | Why? |
| Malaria | 1 | 2006 | 1097 | 0.16 | Why? |
| Pandemics | 19 | 2021 | 389249 | 0.16 | Why? |
| Health Services Accessibility | 1 | 2020 | 10697 | 0.16 | Why? |
| Intensive Care Units, Neonatal | 2 | 2021 | 749 | 0.15 | Why? |
| Prevalence | 7 | 2021 | 25773 | 0.15 | Why? |
| Quality of Life | 1 | 2017 | 9820 | 0.15 | Why? |
| Central Nervous System Infections | 1 | 2018 | 158 | 0.15 | Why? |
| Adult | 23 | 2021 | 244371 | 0.15 | Why? |
| Diagnostic Techniques and Procedures | 1 | 2018 | 265 | 0.15 | Why? |
| Rotavirus | 1 | 2019 | 329 | 0.15 | Why? |
| Critical Care | 2 | 2020 | 14081 | 0.15 | Why? |
| False Positive Reactions | 1 | 2020 | 1338 | 0.14 | Why? |
| Health Personnel | 7 | 2021 | 29646 | 0.14 | Why? |
| Counseling | 1 | 2021 | 747 | 0.14 | Why? |
| Whooping Cough | 1 | 2017 | 201 | 0.14 | Why? |
| Bacterial Infections | 2 | 2021 | 2229 | 0.14 | Why? |
| Neonatal Screening | 1 | 2017 | 285 | 0.14 | Why? |
| Adiposity | 1 | 2017 | 329 | 0.14 | Why? |
| Anti-Bacterial Agents | 6 | 2019 | 10083 | 0.14 | Why? |
| Comorbidity | 2 | 2018 | 34796 | 0.14 | Why? |
| Enterovirus | 1 | 2018 | 402 | 0.13 | Why? |
| Health Services Research | 1 | 2020 | 756 | 0.13 | Why? |
| Perinatal Care | 1 | 2020 | 576 | 0.13 | Why? |
| Surveys and Questionnaires | 6 | 2021 | 43792 | 0.13 | Why? |
| Infectious Disease Transmission, Vertical | 2 | 2021 | 5164 | 0.13 | Why? |
| Child, Hospitalized | 1 | 2017 | 556 | 0.13 | Why? |
| Policy | 1 | 2021 | 1372 | 0.12 | Why? |
| Cerebrospinal Fluid | 1 | 2014 | 234 | 0.12 | Why? |
| History, 21st Century | 2 | 2017 | 1849 | 0.12 | Why? |
| Cluster Analysis | 1 | 2021 | 3001 | 0.12 | Why? |
| Infant, Premature | 1 | 2018 | 883 | 0.12 | Why? |
| Antigens, Viral | 2 | 2021 | 6298 | 0.12 | Why? |
| General Practitioners | 1 | 2020 | 568 | 0.12 | Why? |
| National Health Programs | 1 | 2019 | 807 | 0.12 | Why? |
| Aged | 16 | 2021 | 215776 | 0.12 | Why? |
| Primary Health Care | 3 | 2020 | 4839 | 0.12 | Why? |
| Pediatric Obesity | 1 | 2017 | 492 | 0.12 | Why? |
| Vaccination Coverage | 1 | 2021 | 1249 | 0.11 | Why? |
| Epidemiological Monitoring | 3 | 2020 | 3493 | 0.11 | Why? |
| Cross-Sectional Studies | 5 | 2021 | 53120 | 0.11 | Why? |
| Overweight | 1 | 2017 | 916 | 0.11 | Why? |
| Sepsis | 2 | 2019 | 3517 | 0.11 | Why? |
| Pregnancy Outcome | 2 | 2021 | 3803 | 0.11 | Why? |
| Universities | 3 | 2021 | 4374 | 0.11 | Why? |
| Cost-Benefit Analysis | 2 | 2018 | 2259 | 0.10 | Why? |
| Systemic Inflammatory Response Syndrome | 2 | 2021 | 6653 | 0.10 | Why? |
| Brain Neoplasms | 1 | 2017 | 669 | 0.10 | Why? |
| Cancer Survivors | 1 | 2017 | 588 | 0.10 | Why? |
| Health Care Surveys | 1 | 2020 | 2942 | 0.10 | Why? |
| Genotype | 2 | 2019 | 4697 | 0.10 | Why? |
| Hospitals, Maternity | 2 | 2021 | 154 | 0.10 | Why? |
| Patient Participation | 1 | 2017 | 829 | 0.10 | Why? |
| Immunization, Secondary | 1 | 2017 | 1649 | 0.10 | Why? |
| Coronavirus Infections | 8 | 2020 | 253789 | 0.10 | Why? |
| Community-Acquired Infections | 2 | 2019 | 2328 | 0.10 | Why? |
| Medication Adherence | 1 | 2019 | 1270 | 0.10 | Why? |
| Long-Term Care | 1 | 2021 | 2047 | 0.09 | Why? |
| Gestational Age | 1 | 2014 | 1488 | 0.09 | Why? |
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2021 | 13720 | 0.09 | Why? |
| Pneumonia, Viral | 7 | 2020 | 243684 | 0.09 | Why? |
| Communicable Disease Control | 4 | 2021 | 29620 | 0.09 | Why? |
| Immunization | 1 | 2017 | 2019 | 0.09 | Why? |
| Betacoronavirus | 7 | 2020 | 204454 | 0.09 | Why? |
| Gastrointestinal Diseases | 2 | 2020 | 2580 | 0.09 | Why? |
| Immunity, Cellular | 1 | 2021 | 3614 | 0.09 | Why? |
| Disease Susceptibility | 1 | 2021 | 4002 | 0.08 | Why? |
| Parents | 1 | 2021 | 2758 | 0.08 | Why? |
| Asymptomatic Infections | 3 | 2021 | 7218 | 0.08 | Why? |
| State Medicine | 1 | 2021 | 2847 | 0.08 | Why? |
| Multilocus Sequence Typing | 2 | 2018 | 264 | 0.08 | Why? |
| Carrier State | 1 | 2018 | 2100 | 0.08 | Why? |
| Hospitalization | 4 | 2021 | 54280 | 0.08 | Why? |
| CD4-Positive T-Lymphocytes | 1 | 2021 | 4545 | 0.08 | Why? |
| Databases, Factual | 1 | 2020 | 6248 | 0.07 | Why? |
| RNA, Viral | 5 | 2021 | 32276 | 0.07 | Why? |
| Fatal Outcome | 1 | 2014 | 3438 | 0.07 | Why? |
| Pediatrics | 1 | 2020 | 2969 | 0.07 | Why? |
| Genome, Bacterial | 2 | 2018 | 446 | 0.07 | Why? |
| Practice Guidelines as Topic | 2 | 2020 | 15421 | 0.07 | Why? |
| Antigens, Bacterial | 2 | 2017 | 330 | 0.07 | Why? |
| Middle Aged | 12 | 2021 | 270681 | 0.07 | Why? |
| Acute Disease | 1 | 2017 | 6029 | 0.07 | Why? |
| Case-Control Studies | 2 | 2021 | 17671 | 0.07 | Why? |
| Treatment Outcome | 4 | 2018 | 51732 | 0.07 | Why? |
| CD8-Positive T-Lymphocytes | 1 | 2021 | 5837 | 0.07 | Why? |
| Travel | 2 | 2017 | 7220 | 0.07 | Why? |
| Virus Shedding | 1 | 2020 | 5834 | 0.06 | Why? |
| Olfaction Disorders | 1 | 2020 | 3704 | 0.06 | Why? |
| Follow-Up Studies | 2 | 2018 | 17020 | 0.06 | Why? |
| Nasopharynx | 1 | 2021 | 10224 | 0.06 | Why? |
| Patient Safety | 1 | 2017 | 4885 | 0.06 | Why? |
| Cesarean Section | 2 | 2021 | 2089 | 0.05 | Why? |
| Infant, Small for Gestational Age | 1 | 2021 | 151 | 0.05 | Why? |
| Obstetric Labor Complications | 1 | 2021 | 119 | 0.05 | Why? |
| Caribbean Region | 1 | 2021 | 349 | 0.05 | Why? |
| Mortality | 1 | 2017 | 7132 | 0.05 | Why? |
| Postpartum Hemorrhage | 1 | 2021 | 144 | 0.05 | Why? |
| Diagnosis, Differential | 1 | 2014 | 7220 | 0.05 | Why? |
| Congenital Abnormalities | 1 | 2021 | 170 | 0.05 | Why? |
| Neonatology | 1 | 2020 | 84 | 0.05 | Why? |
| Microbial Sensitivity Tests | 2 | 2018 | 2886 | 0.05 | Why? |
| Polymerase Chain Reaction | 1 | 2014 | 6740 | 0.05 | Why? |
| Premature Birth | 2 | 2021 | 2151 | 0.05 | Why? |
| Interleukin-2 | 1 | 2021 | 443 | 0.05 | Why? |
| Seizures | 2 | 2018 | 1163 | 0.05 | Why? |
| Watchful Waiting | 1 | 2021 | 276 | 0.05 | Why? |
| Pneumonia | 1 | 2019 | 5652 | 0.05 | Why? |
| South Australia | 1 | 2018 | 123 | 0.05 | Why? |
| Practice Patterns, Physicians' | 1 | 2017 | 4927 | 0.04 | Why? |
| Genome, Viral | 1 | 2020 | 13157 | 0.04 | Why? |
| Intensive Care, Neonatal | 1 | 2020 | 284 | 0.04 | Why? |
| Bacterial Capsules | 1 | 2017 | 39 | 0.04 | Why? |
| Infant Care | 1 | 2020 | 178 | 0.04 | Why? |
| Hearing Tests | 1 | 2017 | 76 | 0.04 | Why? |
| Interrupted Time Series Analysis | 1 | 2021 | 868 | 0.04 | Why? |
| Global Health | 1 | 2021 | 13911 | 0.04 | Why? |
| Enterovirus D, Human | 1 | 2018 | 96 | 0.04 | Why? |
| Parturition | 1 | 2021 | 514 | 0.04 | Why? |
| Coma | 1 | 2018 | 204 | 0.04 | Why? |
| Northern Ireland | 1 | 2017 | 228 | 0.04 | Why? |
| Odds Ratio | 2 | 2018 | 5861 | 0.04 | Why? |
| Antibiotic Prophylaxis | 1 | 2018 | 399 | 0.04 | Why? |
| Enterovirus A, Human | 1 | 2018 | 180 | 0.04 | Why? |
| Acetaminophen | 1 | 2018 | 326 | 0.04 | Why? |
| Emergency Service, Hospital | 1 | 2020 | 14232 | 0.04 | Why? |
| Immunologic Surveillance | 1 | 2015 | 69 | 0.04 | Why? |
| Time Factors | 4 | 2021 | 31397 | 0.04 | Why? |
| Case Management | 1 | 2017 | 285 | 0.04 | Why? |
| Capsid Proteins | 1 | 2018 | 365 | 0.04 | Why? |
| Feces | 2 | 2019 | 4235 | 0.03 | Why? |
| Logistic Models | 2 | 2021 | 9089 | 0.03 | Why? |
| Chi-Square Distribution | 1 | 2017 | 961 | 0.03 | Why? |
| Phylogeny | 3 | 2018 | 13341 | 0.03 | Why? |
| Antimalarials | 1 | 2006 | 2505 | 0.03 | Why? |
| Immunoglobulin G | 1 | 2017 | 21571 | 0.03 | Why? |
| Vaccines, Attenuated | 1 | 2019 | 952 | 0.03 | Why? |
| Prognosis | 1 | 2017 | 32490 | 0.03 | Why? |
| Central Venous Catheters | 1 | 2015 | 188 | 0.03 | Why? |
| Public Health Practice | 1 | 2021 | 945 | 0.03 | Why? |
| Propensity Score | 1 | 2021 | 2690 | 0.03 | Why? |
| Body Temperature | 1 | 2018 | 875 | 0.03 | Why? |
| Obstetrics | 1 | 2020 | 859 | 0.03 | Why? |
| Patient Education as Topic | 1 | 2021 | 1476 | 0.03 | Why? |
| Coronavirus | 1 | 2020 | 18339 | 0.03 | Why? |
| Multiplex Polymerase Chain Reaction | 1 | 2019 | 1439 | 0.03 | Why? |
| Phosphoproteins | 1 | 2021 | 4346 | 0.03 | Why? |
| Retrospective Studies | 2 | 2019 | 105322 | 0.03 | Why? |
| Minority Groups | 1 | 2021 | 1631 | 0.03 | Why? |
| Molecular Epidemiology | 1 | 2016 | 1638 | 0.03 | Why? |
| Phenotype | 1 | 2021 | 4037 | 0.02 | Why? |
| Social Determinants of Health | 1 | 2021 | 1757 | 0.02 | Why? |
| Immunity | 1 | 2021 | 2651 | 0.02 | Why? |
| Drug Resistance, Bacterial | 1 | 2018 | 1414 | 0.02 | Why? |
| Proportional Hazards Models | 1 | 2021 | 6543 | 0.02 | Why? |
| Health Care Costs | 1 | 2016 | 1007 | 0.02 | Why? |
| Netherlands | 1 | 2017 | 3533 | 0.02 | Why? |
| Symptom Assessment | 1 | 2020 | 4967 | 0.02 | Why? |
| Multivariate Analysis | 1 | 2017 | 5440 | 0.02 | Why? |
| Serologic Tests | 1 | 2020 | 4359 | 0.02 | Why? |
| Polymorphism, Single Nucleotide | 1 | 2018 | 3607 | 0.02 | Why? |
| Risk Assessment | 2 | 2021 | 25439 | 0.02 | Why? |
| Risk | 1 | 2017 | 5288 | 0.02 | Why? |
| Longitudinal Studies | 1 | 2020 | 9893 | 0.02 | Why? |
| Genetic Variation | 1 | 2019 | 3919 | 0.02 | Why? |
| Clinical Laboratory Techniques | 2 | 2020 | 23402 | 0.02 | Why? |
| Research Design | 1 | 2018 | 5830 | 0.01 | Why? |
| Clinical Trials as Topic | 1 | 2021 | 7330 | 0.01 | Why? |
| C-Reactive Protein | 1 | 2018 | 7972 | 0.01 | Why? |
| Patient Discharge | 1 | 2017 | 5696 | 0.01 | Why? |
| Triage | 1 | 2020 | 7151 | 0.01 | Why? |
| Hospitals | 1 | 2021 | 11793 | 0.01 | Why? |
| Europe | 1 | 2018 | 12702 | 0.01 | Why? |
| Models, Statistical | 1 | 2018 | 5312 | 0.01 | Why? |
| Host-Pathogen Interactions | 1 | 2021 | 11041 | 0.01 | Why? |
| Emergency Medical Services | 1 | 2016 | 3557 | 0.01 | Why? |
| Viral Load | 1 | 2020 | 15850 | 0.01 | Why? |
| Liver Diseases | 1 | 2015 | 2698 | 0.01 | Why? |
| Randomized Controlled Trials as Topic | 1 | 2018 | 10649 | 0.01 | Why? |
| Hospital Mortality | 1 | 2020 | 22087 | 0.01 | Why? |
| Respiration, Artificial | 1 | 2020 | 22116 | 0.01 | Why? |
| Intensive Care Units | 1 | 2021 | 29594 | 0.01 | Why? |